publication date: Feb. 21, 2014


CL40-08b.html


Enrollment in NCI-sponsored National Clinical Trials Network clinical trials will drop to about 17,500 this fiscal year, the network groups have been told by NCI officials.

This enrollment figure includes 3,600 pediatric patients, so the total adult enrollment will add up to about 14,000, insiders at cooperative groups say.

Additional 2,600 patients will undergo screening to determine whether they have the appropriate molecular markers to be eligible for an NCTN trial.

In recent years, enrollment in the institute’s cooperative group trials has been in the range of 20,000 to 23,000. In 2009, enrollment reached a high of 29,200. That year’s accrual included a large screening component associated with one of the largest breast cancer studies ever conducted by the group program.

The groups will be reorganized on March 1 and will become a part of the NCI National Clinical Trials Network. NCTN’s mission includes launching a new generation of genomically-guided clinical trials (see story on p. 1).

Recently, officials at the Gynecologic Oncology Group—which has merged with the former National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group into a single network group called NRG Oncology—said that accrual in all of its phase III trials has been reduced to 201 patients per year.

By way of comparison, in 2010 and 2012 phase III trial accrual in GOG trials averaged 2,190.

“This 90 percent reduction in phase III trial accrual will eradicate the existing gynecologic oncology clinical trials network,” GOG officials wrote in a recent white paper addressed to NCI.

Continue reading 40-08 NCI Clinical Trials Enrollment Drops to 17,500
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.